The European Hematology Association is organizing its 30th EHA Congress, taking place in Milan from June 12–15, 2025, EHA2025. Focus of this years' congress is cutting-edge evidence-based approaches to diagnosis and treatment, highly anticipated clinical and translational research data and the newest developments in innovative techniques, diagnostic tools, and risk-assessment strategies. EHA2025 knows no bounds and is intended for medical professionals, national hematology societies, patient groups, medical industry, and media worldwide.
SYNTHIA Partners plan to participate - and are looking forward to connect - please stay tuned.
SYNTHIA is addressing these challenges head-on by developing validated tools and methods for synthetic data generation (SDG) across various data types, including laboratory results, clinical notes, genomics and imaging. By focusing on six specific diseases - use cases - SYNTHIA will demonstrate the utility of synthetic data in advancing personalized medicine of which are two blood cancers: Multiple myeloma, Diffuse large B-cell lymphoma.
